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post-traumatic stress disorder (PTSD): study
protocol for a pilot randomized controlled trial
with blinded, staggered onset of stimulation
Ralph J Koek1,2,9*, Jean-Philippe Langevin2,3, Scott E Krahl2,4, Hovsep J Kosoyan2,4, Holly N Schwartz1,2,
James WY Chen2,5, Rebecca Melrose2,6, Mark J Mandelkern2,7,8 and David Sultzer1,2Abstract
Background: Combat post-traumatic stress disorder (PTSD) involves significant suffering, impairments in social and
occupational functioning, substance use and medical comorbidity, and increased mortality from suicide and other
causes. Many veterans continue to suffer despite current treatments. Deep brain stimulation (DBS) has shown promise
in refractory movement disorders, depression and obsessive-compulsive disorder, with deep brain targets chosen by
integration of clinical and neuroimaging literature. The basolateral amygdala (BLn) is an optimal target for
high-frequency DBS in PTSD based on neurocircuitry findings from a variety of perspectives. DBS of the BLn was
validated in a rat model of PTSD by our group, and limited data from humans support the potential safety and
effectiveness of BLn DBS.
Methods/Design: We describe the protocol design for a first-ever Phase I pilot study of bilateral BLn high-frequency DBS
for six severely ill, functionally impaired combat veterans with PTSD refractory to conventional treatments. After
implantation, patients are monitored for a month with stimulators off. An electroencephalographic (EEG) telemetry session
will test safety of stimulation before randomization to staggered-onset, double-blind sham versus active stimulation for
two months. Thereafter, patients will undergo an open-label stimulation for a total of 24 months. Primary efficacy
outcome is a 30% decrease in the Clinician Administered PTSD Scale (CAPS) total score. Safety outcomes include extensive
assessments of psychiatric and neurologic symptoms, psychosocial function, amygdala-specific and general
neuropsychological functions, and EEG changes. The protocol requires the veteran to have a cohabiting significant other
who is willing to assist in monitoring safety and effect on social functioning. At baseline and after approximately one year
of stimulation, trauma script-provoked 18FDG PET metabolic changes in limbic circuitry will also be evaluated.
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Discussion: While the rationale for studying DBS for PTSD is ethically and scientifically justified, the importance of the
amygdaloid complex and its connections for a myriad of emotional, perceptual, behavioral, and vegetative functions
requires a complex trial design in terms of outcome measures. Knowledge generated from this pilot trial can be used to
design future studies to determine the potential of DBS to benefit both veterans and nonveterans suffering from
treatment-refractory PTSD.
Trial registration: PCC121657, 19 March 2014.
Keywords: Stress disorders, Post-traumatic, Veteran’s health, Deep brain stimulation, Amygdala, Positron emission
tomography, Electroencephalograms, Caregivers, Controlled clinical trial, NeuropsychiatryBackground
Overview
The present paper discusses the rationale and method-
ology for experimental use of deep brain stimulation
(DBS) for treatment-refractory combat post-traumatic
stress disorder (PTSD). DBS is an invasive treatment, and
the potential for benefits must clearly outweigh the risks.
Potential benefits exist for patients whose illness does not
respond to currently available, lower risk treatments and
continue to suffer severe symptomatic and functional im-
pairment, and these benefits depend on the plausibility of
benefit from direct neurocircuitry modulation with DBS
electrodes. Risks include those of the surgical procedure,
implanted hardware, and of stimulation, along with poten-
tial ethical and social implications. This paper outlines our
weighing of these considerations in the preparation of a
first-ever trial of DBS for PTSD, targeting the basolateral
nucleus of the amygdala (BLn).
The risks of chronic, treatment-resistant combat
post-traumatic stress disorder
PTSD is a serious psychiatric condition that affects an
estimated 6.8% of the US population at some point in
their lifetime [1] with a 12-month prevalence of 3.5%
[2]. Military combat is the classic precipitant of PTSD,
and the prevalence of the condition is significantly
greater among combat veterans than in the general
population. Lifetime/current prevalence in Vietnam
veterans in a well-known 1990 survey was 30.9%/15.2%
for men and 26.9%/8.1% for women [3]. In Gulf War
veterans, 12.1% of a sample of 30,000 had a current
diagnosis of PTSD [4]. Among Operation Iraqi Free-
dom/Operation Enduring Freedom (OIF/OEF) veterans,
one investigation [5] found that 13% met criteria for
PTSD at some point after discharge, while in two other
studies, 13.8% and 14% met criteria for current PTSD
[6,7]. A 2008 study found that PTSD or depression
among troops deployed to Iraq and Afghanistan cost the
US government $6.2 billion [6]. Persistent severe PTSD
was found to be associated with significant distress and
dysfunction.PTSD is defined [8,9] by the occurrence of distressing
or disabling perceptual, emotional, and behavioral changes
that persist after an experience in which the sufferer has
witnessed or been threatened with death or severe injury.
In the 3rd and 4th editions of the American Psychiatric
Association’s (APA) Diagnostic and Statistical Manual of
Mental Disorders (DSM-III, IIIR, IV and IV-R), PTSD was
characterized by three clusters of psychiatric symptoms.
The first, re-experiencing, involves the emotional and per-
ceptual reliving of traumatic event(s) either spontaneously
or in response to ‘triggers’ that remind one of the event
because they bear some similarity to the original circum-
stance. The next symptom cluster, avoidance and numb-
ing, involves the tendency to social isolation and reduced
ability to experience positive emotions in relationships
with others. The hyperarousal cluster includes hypervigi-
lance about one’s surroundings, sleep disturbance, anxiety,
and anger dyscontrol, including physical violence. In the
recently published DSM-5, a 4th cluster of symptoms,
called ‘negative alterations in cognitions and mood’, has
been added. This incorporates several symptoms previ-
ously included in the DSM-IV avoidance and numbing
cluster, and adds persistent distorted blame of self or
others, and persistent negative emotional state as new
symptoms, based on empirical data on the phenomen-
ology of the condition published since DSM-IV [10]. An-
other new symptom, reckless or self-destructive behavior,
was added to the hyperarousal cluster, now termed ‘alter-
ations in arousal and reactivity’.
Individuals with this condition, particularly PTSD
due to combat, suffer terribly [11]. Among Vietnam
veterans, chronic PTSD is associated with less life satis-
faction and happiness [12], increased rates of major de-
pression [13], impaired family functioning [12], marital
problems [14], occupational disability [11], substance
use disorders [15], general medical illnesses [16], and
suicide [17] compared with the general population. One
sobering study found a 17% mortality rate over six years
of follow-up in 51 Vietnam combat veterans, despite in-
tensive treatment at the National Center for PTSD in
New Haven (NCPTSD) [18]. PTSD with psychotic
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uals with this condition [19]. Unfortunately, PTSD in
OIF/OEF veterans is associated with social and medical
morbidity similar to that suffered by Vietnam veterans
[20-23].
Current treatments for PTSD include psychotropic
medications and/or psychotherapy. Antidepressants are
commonly prescribed. The selective serotonin reuptake
inhibitor (SSRI) antidepressants, sertraline and paroxe-
tine, are the only US Food and Drug Administration
(FDA) approved medications for the condition. It is
worth noting, however, that <10% of patients in the tri-
als leading to FDA approval were combat PTSD suf-
ferers [24-27], and at least three trials in combat PTSD
failed to demonstrate better efficacy with an SSRI than
placebo [28,29]. Recent guidelines conclude that the evi-
dence now does not provide strong support for the use
of SSRIs for combat PTSD [30,31]. Venlafaxine, in a
mixed-trauma population [32], and prazosin, in veterans
and active duty military personnel [33,34], have both
shown efficacy in placebo-controlled trials, and several
other medications have at least open-label findings in
favor of benefit for combat veterans. But, except for the
most recent study of prazosin [34], none of these have
demonstrated efficacy in large randomized controlled
trials (RCTs). Some commonly used pharmacologic
strategies, including second-generation antipsychotic
augmentation of unsuccessful antidepressant therapy, as
well as divalproex and bupropion, have failed to separ-
ate from placebo in RCTs with combat vets, and one
very commonly used medication class - benzodiazepines
- while widely used in clinical settings, has no good sup-
porting evidence, and is described as not effective and
potentially harmful in the recent NCPTSD treatment
guideline [31].
Individual or group psychotherapies are also provided for
veterans with PTSD. The NCPTSD considers Prolonged
Exposure therapy (PE) [35-37], Cognitive Processing Ther-
apy (CPT) [38,39], and Eye Movement Desensitization and
Reprocessing (EMDR) [40-42] treatments of proven effi-
cacy. Each of these evidence-based therapies involves a
component of exposing patients to anxiety-evoking re-
minders of the traumatic experience(s). Exposure-based
treatments are found by most investigators to be the most
effective therapeutic interventions [43-45]. This was also
the position of the Institute of Medicine’s 2007 report [46].
Recently, Eftekhari and colleagues [47] published results
from a national roll-out of Prolonged Exposure Therapy
(PE) for combat-related PTSD carried out in a manualized,
but open-label fashion by United States Department of
Veterans Affairs practitioners across the country. Nearly
50% of patients achieved the response criterion of 50% re-
duction in PTSD according to the PTSD Checklist-Military
Version [48] after a mean of 11.6 weekly sessions. In aseparate report, Goodson and colleagues [49] also found
significant benefit with PE among a group of veterans with
predominantly combat PTSD. Tuerk et al. (2011) [50] also
found PE effective for PTSD in OEF/OIF combat veterans.
Combat PTSD is generally more severe and has a
lower rate of remission than noncombat PTSD [51,52].
A meta-analysis of controlled psychotherapy and psy-
chopharmacology trials found that overall, nearly 2/3 of
patients treated with exposure therapy who completed
treatment no longer met criteria for PTSD, but treat-
ment response was significantly poorer in combat com-
pared to noncombat PTSD [53]. In a study of Hispanic
and American Indian veterans, only 20% of 106 with
combat PTSD had experienced a year or longer without
symptoms since onset, in contrast to 40% of veterans
with PTSD from noncombat trauma [51]. In a long-
term follow-up study of over 200 Israeli combat vet-
erans, 26 to 50% were still diagnosed with PTSD 20 years
later [54]. In OEF/OIF veterans, PTSD is an important
predictor of impaired psychological and physical func-
tioning after deployment [55]. Neuropsychological defi-
cits in OIF veterans worsened in proportion to severity
of PTSD when assessed one year after return from de-
ployment [56]; and in another study, PTSD mediated
the effect of traumatic brain injury (TBI) on psycho-
social function in OEF/OIF veterans [57]. In OEF/OIF
veterans with both mild TBI (mTBI) and PTSD, PTSD
accounts for more impairment on neuropsychological
testing than mTBI [58,59]. Overall, long-term outcomes
with even the most intensive treatments reveal persist-
ent suffering and disability for many veterans, even
when there is significant symptomatic improvement
[60-62].
New treatments are sorely needed for the large num-
ber of patients who are left with significant disability
and suffering despite the best current care. Intrusive
and hyperarousal cluster symptoms are in particular
more severe in combat PTSD [63,64], and decreased re-
experiencing symptoms over time is associated with
improvement in occupational, social, and family func-
tioning [65]. Our novel strategy, involving direct neuro-
modulation, targets the amygdala based on research
that demonstrates an association of intrusive and cue-
induced hyperarousal symptoms with overactivity in this
brain region. If the results of this project are positive, it
will have direct benefit for veterans suffering from
treatment-resistant PTSD and will contribute to under-
standing the pathophysiology of the condition.
Deep brain stimulation
Deep brain stimulation (DBS) refers to the process of
delivering an electrical current to a precise location in
the brain. DBS is now a common clinical practice and
more than 100,000 patients have been implanted [66].
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disease and essential tremor, the first conditions to have
shown benefit in systematic investigations comparing
DBS to best medical therapy. Surgical targeting is based
on specific neurocircuitry models. Because of the signifi-
cant long-term benefit, including reduced mortality com-
pared to alternatives in treatment-refractory Parkinson’s
Disease [67], DBS has largely replaced targeted ablative
neurosurgery.
For psychiatric disorders, DBS was also first studied in
conditions for which targeted ablative neurosurgery has
been used to treat the most severely ill patients, who do
not respond to available, less invasive treatments. With
the first reported cases in obsessive-compulsive disorder
(OCD) in 2003 [68] and major depression in 2005 [69],
DBS was found to have the capacity to produce response
in patients who had previously been refractory to all
standard interventions. In OCD, long-term benefit has
been repeatedly demonstrated across different investiga-
tive centers [70-72], such that the US FDA granted a
Humanitarian Device Exemption for Anterior Limb of
the Internal Capsule (ALIC) DBS on a case-by-case
basis. Beneficial effects for treatment-refractory depres-
sion have also been replicated by investigators in various
countries [73-77], but DBS for this condition remains
experimental. Reviewers have found response and remis-
sion rates in both conditions in the range of 25 to 50%
[78-80] with benefits maintained or accrued over at least
the first three years, and significant improvement in
functioning as well as symptomatology [70,81,82]. Other
psychiatric conditions in which DBS is under active
study include addiction [83], Alzheimer’s disease [84],
and anorexia nervosa [85].
In its current application, DBS electrical current is mod-
ulated by frequency, pulse width, and amplitude. These
parameters can be modified postoperatively with an exter-
nal programmer. Reversibility is an obvious benefit of this
treatment over resection or a destruction procedure.
While the exact mechanism of action is not yet fully
understood, it is relevant that the brain is a voltage sensi-
tive organ, composed of numerous ion channels with
different voltage sensitivity and activation ranges. The
neurophysiological responses from an electrical stimula-
tion can be determined from the voltage changes at a spe-
cific tissue site and the subsequent activations of ion
channels. Variations of how the stimulating current is de-
livered, such as by changing the stimulation pulse width,
the amplitude and the frequency, would result in differ-
ences in the extent of tissues that could reach the target
voltage. The stimulated tissues could be modeled as a
sphere with the tip of the stimulation electrode at the cen-
ter. The stimulation effect, or the induced voltage change,
is impedance dependent and tapers down, moving further
away from the center of stimulation. After a tissue isstimulated, the activation of various ion channels subse-
quently plays an active role in determining the final
neurophysiological effects [86]. Clinically, we can approxi-
mate the stimulated effect as pulse width determines the
surface area of neural tissue covered by the stimulation,
amplitude determines the strength of the effect, and fre-
quency determines activation or inhibition. High fre-
quency stimulation blocks the activity of the neural
structure and clinically mimics the effects of a lesion
[87-89], although electrophysiological monitoring has
shown that neural fibers can be activated even with high-
frequency DBS [87]. A current model holds that DBS adds
a significant amount of interference to the final output
signal from the nucleus, therefore rendering the output
signal meaningless. This process is referred to as ‘fre-
quency jamming’. Several other hypotheses of DBS mech-
anisms have been put forward, and it is likely that
mechanisms of action differ in different conditions and
targets. In each of the psychiatric conditions in which it
has been studied, DBS targets have been chosen based on
functional neuroimaging findings of abnormal brain
circuitry. In both depression [73] and OCD [90], high-
frequency DBS targeted to an area of hyperactivity
normalizes metabolism in interconnected brain regions.
Similarly, in Alzheimer’s Disease, functional connectivity
with hippocampus and cerebral cortex increased after
1 year of DBS in the nucleus basalis [91].
Rationale for targeting the amygdala with deep brain
stimulation in post-traumatic stress syndrome
Our planned intervention is based on a well-accepted
model of the pathophysiology of PTSD involving amyg-
dala hyperactivity in association with reminders of the
traumatic event [92]. Research in animal models has
shown that the amygdala mediates emotional and auto-
nomic responses to environmental stimuli generally, and
conditioned fear responses specifically. The amygdala is
a complex, heterogenous gray matter structure in the
medial temporal lobes. It is composed of several subdivi-
sions with different functional roles. Two principal
subdivisions - the lateral nucleus and the central nucleus
- can be conceived of as the receptive and expressive re-
gions of the amygdaloid complex. The basolateral nu-
cleus (BLn) acts as a relay nucleus within the amygdala
by receiving multiple connections from the lateral nu-
cleus and sending efferents to the central nucleus [93].
The BLn forms a connectivity loop with the medial pre-
frontal cortex (mPFC) [94]. This reciprocal connection
is thought to be involved in the cortical (that is, top-
down) control of emotions. The function of the amyg-
dala is to link sensory input to emotional responses that
then guide behavior. The lateral nucleus screens sensory
input, the BLn modulates (suppresses or enhances) these
inputs, and the central nucleus orchestrates the emotional
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in humans also suggest that the amygdala mediates the ac-
quisition, consolidation, and extinction of conditioned fear
responses. When PTSD patients are subjected to imagery
or sounds reminiscent of their trauma and scanned with
functional magnetic resonance imaging (fMRI), positron
emission tomography/computed tomography (PET-CT or
PET), or single photon emission computerized tomog-
raphy (SPECT), there is overactivity in the amygdala com-
pared to normal controls [95-108]. A meta-analysis of
these functional neuroimaging studies found that the
focus of hyperactivity is located in the basal portion of the
amygdala [109]. These authors and other reviewers [110]
found that amygdala hyperactivity is associated with con-
ditioned anxious hyperarousal in several anxiety disorders,
in particular, anxiety disorders in which pathological anx-
iety responses are linked to specific environmental stimuli
(PTSD, social anxiety disorder, and specific phobia). A
more recent meta-analysis of functional neuroimaging
studies involving symptom provocation in PTSD patients
revealed hyperactivation of the bilateral amygdalae, as well
as in midline retrosplenial cortex, precuneus, and pregen-
ual/anterior cingulate gyrus in response to trauma-related
stimuli [111]. Also very recently, Yan and colleagues [112]
found increased amygdala activity in the resting state in
combat veterans with PTSD, compared to those without
PTSD. In PTSD, the intensity of BOLD signals on fMRI
and regional blood flow on 15O2 PET in the amygdala are
positively associated with symptom severity [102,113].
Several authors [114-116] have found that successful
cognitive-behavioral treatment of PTSD is associated
with a reduction in pretreatment amygdala hyperactivity.
Correspondingly, another study found that higher pre-
treatment amygdala activation predicted lower likelihood
of response to exposure therapy in PTSD [113].
Thomaes et al. [117] recently reviewed four randomized
controlled trials and five pre-post studies and found that
in adult-onset trauma-related PTSD, there are decreased
amygdala and increased dorsolateral prefrontal activa-
tions after treatment.
An elegant study using a different methodological
approach has even suggested a causal relationship be-
tween amygdala activation and the development of PTSD
in combat veterans. Koenigs and colleagues [118] sepa-
rated veterans in the Vietnam Head Injury Study (VHIS)
into four groups based on the location of their brain dam-
age and compared the lifetime prevalence of PTSD in each
group with that in a group with no brain injury. In combat
veterans without brain injury, the prevalence of PTSD was
48%. In those with brain damage sparing both the vmPFC
and amygdala, PTSD prevalence was similar at 40%. Most
notably, none of the 15 veterans with amygdala damage
ever developed PTSD. To further evaluate the specificity
of amygdala damage, the authors looked at a subgroupwith temporal lobe lesions sparing the amygdala. In this
group, the rate of PTSD was similar to that in the non-
brain-injured group at 32% [118]. Complementary results
have been seen with structural MRI studies, in which
combat veterans with, versus those without, PTSD have
been shown to have larger amygdala volumes [119], and
smaller volumes of the subgenual anterior cingulate
(sgACC), caudate, hypothalamus, left insula, left middle
temporal gyrus (MTG), and right middle frontal gyrus. In
veterans with PTSD, CAPS scores correlate inversely with
volumes of the sgACC, caudate, hypothalamus, insula,
and left MTG [120].
Fear extinction is likely subserved by a ventromedial
prefrontal cortex (vmPFC) projection to the amygdala.
The vmPFC has a reciprocal connection with the amyg-
dala, and within the amygdala, the BLn forms the main
circuit loop with the vmPFC [121]. The vmPFC projection
to the BLn has been shown in animals to provide an in-
hibitory effect on amygdala activation with extinction of
conditioned fear responses, the latter being mediated by
amygdala output nuclei that receive projections from the
BLn. In addition, the BLn is the primary locus of memory
for aversive conditioned stimulus-unconditioned stimulus
(CS-US) associations [94]. Thus, the inhibitory role of the
vmPFC on the amygdala is likely to be mediated through
the BLn. In those terms, failure of fear extinction in PTSD
can be understood as a failure of inhibition of the BLn by
the vmPFC. Therefore, inhibiting BLn hyperactivity should
restore normal fear extinction in PTSD patients. In a rat
model, enhanced extinction of a conditioned fear re-
sponse by the NMDA-receptor glutamatergic agonist,
d-cycloserine, was localized to the BLn [122].
In humans, the functional neuroimaging review by Etkin
and Wager [109] showed significant hypoactivation of the
vmPFC in PTSD studies, but not in other conditions (for
example, social anxiety disorder and specific phobia) that
also have cue-related fear arousal in association with
amygdala hyperactivation. Resting state fMRI studies of
combat veterans with PTSD completed since we initially
developed this protocol have confirmed and extended this
pattern. In a study of OEF/OIF combat veterans using the
amygdala as a seed, Sripada and colleagues [123] demon-
strated increased amygdala connectivity with the insula
and hypothalamus, and reduced functional connectivity
with the dorsal and rostral anterior cingulate cortex, in
those with, compared to those without, PTSD. Rabinak et
al. [124] also showed increased amygdala-insula connect-
ivity. Hayes and colleagues [125] found a direct correlation
between amygdala hyperactivity and vmPFC hypoactiva-
tion in a quantitative meta-analysis of 26 fMRI and PET
symptom-provocation studies in adult PTSD, even though
their meta-analysis demonstrated amygdala hyperactivity
in studies with cognitive-emotional, but not symptom
-provocation tasks. Most recently, Brown et al. [126]
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those without, PTSD had reduced functional connectivity
between the BLn specifically, and prefrontal regions medi-
ating cognitive control of emotional responses.
Taken together, the findings reviewed suggest the possi-
bility that patients whose PTSD symptoms do not respond
to exposure therapy or other interventions may have unre-
mitting amygdala hyperarousal that is resistant to, or
insufficiently suppressed by, cognitive efforts normally
mediated by vmPFC activation.
Preclinical validation studies of amygdala deep brain
stimulation in post-traumatic stress disorder
Based on the foregoing, it is predicted that high-frequency
DBS of the BLn will reduce the symptoms of PTSD. We
tested this hypothesis in a rat model using inescapable
shocks. Inescapable shocks in rats produce long-lasting
behavior changes that mimic PTSD [127]. Mikics and col-
leagues [128] demonstrated that rats traumatized by in-
escapable shocks, in the presence of a conspicuous object,
had the tendency to bury the object when re-exposed to it
28 days later. Burying behavior does not occur normally in
rats. The behavior models PTSD faithfully in that it is
maintained over several weeks without signs of extinction,
it is generalized to other objects than the one originally
presented and the rats also displayed sustained social
avoidance [128]. The behavior is robust and the majority
of rats will have buried the object completely at the end of
a 10-minute observation period, making this model at-
tractive for studies.
We conducted two rodent studies using this PTSD
model and high-frequency BLn DBS as a treatment. In the
first study [129], we showed that DBS of the right BLn
corrected the object-burying behavior following inescap-
able shocks in rats. The difference in behavior was strik-
ing. The sham control rats spent on average 13 times
more time burying the ball than the DBS-treated rats
(P <0.005), while the latter spent 18 times more time ex-
ploring the ball. In the second study, we showed that BLn
DBS, but not paroxetine, reduced burying behavior follow-
ing inescapable shocks [130]. In that study, we used a
crossover design with real versus sham DBS, each admin-
istered for one week. We demonstrated that 1) BLn DBS
was effective at one week, and the effects persisted after
another week of sham treatment, and 2) BLn DBS was ef-
ficacious when the initiation of the therapy was delayed
for a week after establishment of the behavior, modeling
chronic PTSD. In addition we tested whether the effect of
DBS on ball burying behavior was due to a general pattern
of behavioral inhibition. This was assessed using the ele-
vated plus maze, a model for assessing general anxiety, fol-
lowing the last burying behavior evaluation at 14 days.
Rats treated with paroxetine spent significantly more time
in the open arms, suggesting a reduction in generalanxiety. The animals treated with DBS showed no signifi-
cant difference. These results suggest that paroxetine car-
ries its therapeutic effects on PTSD through a nonspecific
reduction in general anxiety, while DBS improves PTSD
without such nonspecific anxiety-reducing effects. The
DBS-treated rats did not exhibit signs of fearlessness or
carefree behavior during the trial. The animals treated
with DBS in this study also did not display abnormal or
violent behavior.
Other preclinical studies [131,132] have reported that
DBS of the amygdala and the hippocampus respectively
raised the threshold for electroconvulsion, therefore
leading to protection against seizures. In humans,
chronic high-frequency stimulation of mesiotemporal
structures has been shown to raise the seizure thresh-
old. Velasco et al. [133] reported that the chronic high-
frequency stimulation of the normal or the sclerotic
hippocampus reduce the incidence of seizures in refrac-
tory epileptic patients without causing side effects.
Patients with normal hippocampus had a 95% seizure
reduction; patients with a sclerotic hippocampus had 50
to 70% seizure reduction.
Prior findings with amygdala neurosurgery in humans
In stereotactic amygdalotomy, destructive lesions are
created in both amygdalae using radiofrequency abla-
tion for patients suffering from intractable aggression.
The procedure was performed primarily in the 1960’s
and the 1970’s. Narabayashi [134] introduced the stereo-
tactic amygdalotomy in the 1960’s. Initially, the proced-
ure was offered to patients suffering from epilepsy or
EEG abnormality in addition to aggressive behavior, but
eventually it was offered more broadly to patients suf-
fering from ‘intractable aggression’. Following this initial
report, several other authors reported their outcomes
for the treatment of aggression and over a thousand pa-
tients have been treated [135-137]. The overall improve-
ment in symptoms reported range between 33 and
100%, with most authors reporting 70 to 85% improve-
ment [138]. Lee and colleagues (1998) [139] reported
two patients who underwent stereotactic amygdalotomy
for intractable aggression and demonstrated specifically
reduced behavioral and autonomic ‘fight or flight’ acti-
vation in response to stressful cues. In these reports of
stereotactic amygdalotomy, the amygdala was safely
approached through a transfrontal trajectory by many
investigators. Large lesions were created using wax,
ethanol, or radiofrequency ablation with the goal of
complete destruction of bilateral amygdala. The size of
those lesions was approximately 10 to 20 times the
diameter of the current DBS electrode. Despite the large
lesions, in his series of 60 patients, Narabayashi et al.
[134] observed no psychological disturbance from the
procedure and only one case of transient weakness that
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leagues [140] reported seven complications following 18
operations. There were four cases of new-onset epilepsy
and three cases of hypersexual behavior. The epilepsy
resolved over a period of several months. Since those re-
ports, surgical and imaging techniques have evolved
considerably. Thus, no complications were reported in a
more recent study where modern stereotactic and abla-
tive techniques were used [139].
Since the advent of DBS, destructive procedures, such as
subthalamotomy and thalamotomy to treat Parkinson’s dis-
ease and tremor have become obsolete. This has occurred
because the safety profile of DBS is superior to destructive
strategies. With minimal disruption of the cerebral tissue,
the risks of hemorrhage, stroke and neurological deficits
are significantly reduced. In addition, neuromodulation is
reversible and side effects can often be corrected with pro-
gramming changes.
There is a case report of inadvertent DBS of the main
amygdala output, the stria terminalis [141]. A patient
underwent the placement of bilateral globus pallidum
interna (GPi) DBS electrodes (model 3387, Medtronic, MN,
USA) for the treatment of dystonia. There was improve-
ment in dystonia at the 4-month follow-up visit. Apparently
soon thereafter, the left-sided electrode inadvertently mi-
grated to the area of the stria terminalis, the major white
matter tract output from the amygdala. The left electrode
delivered stimulation at the following parameters: 2.7 V
(amplitude), 180 μsec (Pulse width) and 180 Hz (fre-
quency). Over the next five months, the patient developed
symptoms of depression, apathy, irritability, hopelessness,
and suicidality. Once the electrode was repositioned, the
patient’s symptoms resolved completely. His neuropsycho-
logical condition remained unchanged from preoperative
assessments through 9 total months of stimulation.
DBS of white matter tracts, like the stria terminalis, is
known to cause an increase of the activity of the tract
and its neuronal targets. This phenomenon commonly
leads to DBS side-effects such as muscular contractions,
which are due to internal capsule (white matter tract)
stimulation, or diplopia, from oculomotor nerve stimula-
tion (also white matter). In essence, DBS of the stria ter-
minalis equates to the state of amygdala overactivity
seen in PTSD patients. On the contrary, gray matter
DBS has been shown clinically and by functional neuro-
imaging to reduce the metabolic activity of surrounding
areas and neuronal targets [73]. Therefore, DBS of gray
matter, such as the BLn, would likely have effects oppos-
ite those seen from DBS of the white matter in the case
of the amygdala. This case is critical for several reasons:
1. It supports the model that amygdala overactivity is
responsible for the symptoms of PTSD. DBS of the
stria terminalis physiologically equates to amygdalaoveractivity. In this patient with no psychiatric
history, an increase in amygdala output activity has
led to symptoms commonly seen in combat PTSD
(for example, irritability, helplessness, depression,
and suicidality).
2. The correction of the amygdala activity led to
resolution of the symptoms. As opposed to DBS of
the stria terminalis, BLn DBS is expected to reduce
amygdala output.
3. The patient did not suffer from a seizure or
deterioration in neuropsychological status during
chronic DBS for nine months. This suggests an
acceptable safety profile of DBS of the amygdala.
Very recently, Sturm and colleagues [142] (2013) ap-
plied conventional DBS bilaterally to the BLn in a 13-year-
old boy with intractable self-injurious behavior (SIB) in
the context of mental retardation and Kanner’s autism.
Over the course of 26 months follow-up at the time of
publication, the authors described clinically significant im-
provement in SIB, as well as social communication and
even language function; the child had not previously de-
veloped language and spoke for the first time beginning
six months after DBS. Notably, only stimulation of the
BLn, but not the central nucleus, the amygdala outflow
tract, or neighboring regions affected by other contacts of
the stimulating electrodes, led to benefit. Also important
was the absence of significant side effects, including sei-
zures. There was no benefit from insertion without stimu-
lator activation, and an exacerbation occurred consequent
to battery depletion with reinstatement of benefit after re-
initiation of stimulation. Electrode insertion trajectory and
stimulation parameters used in that single case corres-
pond closely to those planned in the present investigation
(transfrontal (Figure 1); 130 Hz, 120-μsec pulse width, 2
to 6.5-V amplitude).
Electrical stimulation of the amygdala in humans has
also been performed in patients undergoing depth elec-
trodes for epilepsy monitoring [143-145]. The amplitude
delivered to the tissue was up to 10 mA, several fold
higher than the recommended DBS parameters. The
smaller diameter of those electrodes compared to the
current DBS implant also means that the charge density
delivered was several times higher than the maximum
allowed by the Medtronic Activa system we will use in
this study. In addition, the frequency was kept low: be-
tween 5 to 10 Hz, approximately 10 to 20 times lower
than currently used for movement disorders, and 20 to
30 times lower than planned in this investigation. These
settings were meant to generate seizures or other symp-
toms that would be related to the amygdala. The authors
were intrigued that very few patients reported significant
anger despite the elevated settings of stimulation. In
addition, few convulsions were noted despite the high-
Figure 1 Transfrontal trajectory for deep brain stimulation of the basolateral amygdala.
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from medically refractory temporal lobe epilepsy [143]. In
our protocol, the amygdala tissue disruption and the elec-
trical charge density are both several folds (that is, 10 to
20 times) smaller than listed in previous reports concern-
ing amygdala neurosurgery. Therefore, we expect our
safety profile to be considerably better. In addition, we are
benefiting from the advances in surgical and imaging tech-
niques since those reports were published.
Taken together, the data reviewed in the preceding sec-
tions support the proposal that persistent amygdala hyper-
activity, most likely localized to the BLn, underlies the
symptoms of treatment-refractory combat PTSD; a treat-
ment that would directly reduce this hyperactivity could
benefit patients whose symptoms do not respond to
standard treatments. High-frequency DBS of the BLn
could do this without significant risk of causing seizures
or other major behavioral changes. We recognize that, as
in other neuropsychiatric disorders associated with dys-
function in limbic circuitry, amygdala hyperactivation in
PTSD is likely a node in an interconnected circuit, com-
prising at least the vmPFC, anterior insula, and extended
amygdala, as well as the ventral striatum, with reciprocal
connections to thalamus and hypothalamus, and output
to brainstem nuclei that are also involved in the clinical
phenomenology seen in the condition. While we thus
agree with other investigators [146] that the BLn is not
the only potentially valuable target for DBS in PTSD, we
believe, based on the rationale described above, that it is
the optimal target and it can be modulated safely with
current technology.
Methods/Design
Purpose and justification of the study
The purpose of the current study is to evaluate the
safety and potential therapeutic benefit of the Medtronic
Activa DBS system implanted bilaterally in the BLn of
the amygdalae in combat veterans with severe, chronic,treatment-resistant PTSD. DBS is considered a safe,
nondestructive, and reversible therapy for neurological
and psychiatric conditions. Despite being safe, DBS car-
ries risks related to the surgery as well as risks associated
with the neuromodulation. We expect the rate of com-
plications from the amygdala BLn implantation proced-
ure to be comparable to reported risks in other DBS
applications, as reviewed elsewhere [147] and as detailed
below.
Characterizing potentially undesirable effects of chronic
high-frequency DBS of the amygdala is a principal aim of
the study. While we expect there to be a low risk of serious
adverse effects, the study involves extensive monitoring for
psychiatric, neurologic, and neuropsychological adverse ef-
fects as described below and listed in Additional file 1.
The duration of the investigation will be 24 months
for each subject following device implantation and
randomization. The subjects will be followed biannually
once they exit the protocol. The presence of a signifi-
cant other engaged in the healthcare of the patient will
assist in early detection of adverse effects, as well as
evaluating functional benefits.
We believe the risks involved, and the burden of exten-
sive repeated assessments, are justified because treatment-
resistant PTSD is a very serious illness associated with
significant suffering and morbidity. There are currently no
good treatment options for patients who have failed to
improve with psychotherapy and several lines of psycho-
pharmacological agents. We believe that BLn DBS is a
therapeutic option worth investigating.
Design of the study
This proof-of-concept trial will follow a randomized and
blinded staggered-onset design for the initial three months
after implantation, followed by open-label active stimula-
tion in all subjects for a total of 24 months after implant-
ation, with systematic monitoring of safety and efficacy.
This design has been used in other recent successful early
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ditions [148]. The staggered onset of active stimulation
permits assessment of the possible effect of electrode
insertions without stimulation (‘microlesioning’) of the
amygdala target. We expect greater improvement in
PTSD symptoms in patients with initial active DBS, com-
pared with sham stimulation, and improvement in the
subgroup initially randomized to sham after stimulators
are subsequently activated. The comparison of sham to
active stimulation also permits a direct comparison of
possible adverse effects of BLn DBS to insertion of inactive
electrodes. We feel that the 2-month delay in receiving ac-
tive treatment for those subjects randomized to initial
sham stimulation is justified based on the scientific value
of the comparisons noted, given the previously untested
nature of the intervention. For ethical and investigative
reasons, all subjects will receive active stimulation
beginning at three months after implantation. In both
treatment-refractory OCD [72] and depression [81], the
benefits of stimulation increased over a 1- to 2-year period
after initiation, leading us to design this pilot study with a
2-year investigational period after implantation. Given the
chronic nature of illness in the subjects to be included in
this study, it also makes sense heuristically to expect opti-
mal benefit to take up to 2 years to be manifest. Equally
important is the potential for adverse effects of long-term
amygdala DBS to build or change over time.
The study will be conducted at the VA Greater Los
Angeles Healthcare System (GLA) facilities. Several key
elements make GLA the optimal location to conduct
this rigorous trial and insure the safety of the subjects:
1) GLA is one of only six VA Parkinson’s Disease Re-
search, Education and Clinical Care (PADRECC) centers.
As such, GLA routinely conducts DBS procedures for
the treatment of movement disorders. In addition, the
GLA staff has extensive experience with the conduct of
human trials in DBS. They have successfully participated
in several DBS trials, including the cooperative studies
for Parkinson’s disease [149] and the recent SANTE trial
for the treatment of epilepsy [150]. 2) GLA treats a large
PTSD population and has state-of-the-art psychiatric
treatment programs for combat PTSD. The staff has ex-
tensive experience with the treatment of complex
chronic PTSD in an academically affiliated medical cen-
ter (UCLA) with a variety of outpatient programs, in-
cluding PTSD specialty clinics, outpatient mental health
centers in six to eight different communities in the
greater Los Angeles area, pain clinics, post-deployment
clinics, and a domiciliary. Algorithms in place allow for
the safe and efficient treatment of acute psychological
deterioration or transient worsening, including inpatient
psychiatry and neurosurgical services. 3) GLA is also
one of the 16 VA Epilepsy Centers of Excellence (ECoE).
As such, it possesses unique professional expertise andadvanced telemetry equipment for the monitoring, treat-
ment, and prevention of seizures and epilepsy. In addition,
the team has extensive experience with telemetry-related
research.
This is a pilot study and thus will involve only six sub-
jects, two sets of three randomized to either staggered
onset time of initiation of stimulation. We believe this
subject number will adequately address the proof of con-
cept purpose of the study and provide meaningful infor-
mation about the difference between active and sham
stimulation (see above).
The study will provide close follow-up of patients after
DBS surgery by a team involving a functional neurosur-
geon, psychiatrists, an epilepsy specialist neurologist, a
neuropsychologist, a geriatric neuropsychiatrist, functional
neuroimaging experts, and a clinical neurophysiologist, all
with expertise in psychiatric neuroscience, clinical care of
veterans with PTSD, and the use of DBS. Similar to other
recent studies [73,75,151] and guided by consensus recom-
mendations [152,153], we intend to publish de-identified
complete details of individual patient demographic and
clinical descriptors, study procedures and results, neuroim-
aging procedures, and DBS implantation procedures and
stimulation parameters.
Participants
The study has been approved by the GLA Institutional
Review Board (IRB; PCC# 2014 -020159 2-12-14). An in-
dependent Data Safety Monitoring Board (DSMB), to
which data on each subject will be submitted for review
every three months for the first twelve months and then
every six months for the last twelve months, has been
established. The DSMB has already stipulated that the
first subject be monitored for at least six months before
the second subject is enrolled, after which, should there
be no serious safety concerns, parallel enrollment will be
permitted. The study is recruiting subjects, and has been
registered at www.clinicaltrials.gov (PCC# 121657).
Potential subjects are recruited for the study via distri-
bution of flyers to staff at GLA Mental Health Outpatient
programs. Flyers include summarized inclusion and exclu-
sion criteria. Potential subjects are informed about the
study by their treating clinician, and given contact infor-
mation for the study psychiatrist and neurosurgeon if they
are interested. Charts of potential patients are then
reviewed by investigators based on an IRB-issued Waiver
of Consent for Screening. Patients meeting chart-review-
based inclusion and exclusion criteria are invited to attend
an in person assessment for further determination of eligi-
bility. Eligible subjects will sign informed consent. After
this, they will undergo baseline evaluations spaced over a
six-week period, including neuropsychological testing and
a baseline 18FDG PET scan (described below). Patients are
reassessed with the Clinician Administered PTSD Rating
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only those who maintain a total CAPS score ≥85 and
other inclusion and exclusion criteria will be kept in the
study. An additional baseline evaluation is stipulated by
California Law referring to ‘Psychosurgery’ (WIC Sec
5326.6): all potential subjects must undergo examination
by an independent team, consisting of neurosurgeons and
psychiatrists uninvolved in the treatment or the study
protocol, to ascertain capacity to consent, severity of
illness, and inadequacy of response to standard treat-
ments. This team of independent experts is assigned by
the Medical Director of the Los Angeles County Depart-
ment of Mental Health. Concomitant psychotropic medi-
cation regimens will be kept constant for the first six
months of the study, unless medication-related adverse
events, intercurrent medical conditions, or changes in psy-
chiatric status make alterations clinically necessary.
Inclusion criteria
Inclusion criteria include the following:
1. Male aged 25 to 70 years.
2. Able to give informed consent in accordance with
institutional policies and participate in the 2-year
follow-up, involving assessments and stimulator
adjustments.
3. Patients must be stable on their current
psychotropic medication for a period of 2 months
before implantation and agree to not increase
dosages or add any new medications for the first
6 months of the study, unless medically necessary.
4. Chart diagnosis of chronic and treatment-refractory
PTSD as the principal psychiatric diagnosis and
cause of distress and social/occupational
impairment.
5. Confirmation of PTSD as the primary psychiatric
diagnosis by the study psychiatrist via clinical
interview and Clinician Administered Post-traumatic
Stress Disorder Scale (CAPS) [154].
6. Confirmation of combat trauma exposure via
military record review and a Combat Exposure Scale
(CES) [155] score ≥9.
7. Minimum of 5-year total illness duration, with no 6-
month period of clinical remission during the 5 years
prior to entry in the study.
8. Clinical record documentation of nonresponse to at
least 2 of the following antidepressants, alone or in
combination, at maximally tolerated FDA
recommended doses for ≥6 months: sertraline,
paroxetine, fluoxetine, citalopram, escitalopram,
amitriptyline, imipramine, nortriptyline,
desipramine, clomipramine, phenelzine,
tranylcypromine, venlafaxine, mirtazapine.
Antidepressant trials must include at least one SSRIand one SNRI or TCA at maximally tolerated FDA
recommended doses for a minimum of 3 months.
9. A minimum 3 month trial of prazosin at 10 mg per
day or, if less, maximally tolerated FDA
recommended doses, unless considered
contraindicated based on co-morbid medical condi-
tions or concomitant medications.
10. Trial of at least 3 months of one of the following:
lithium, divalproex sodium, carbamazepine,
lamotrigine, olanzapine, risperidone, bupropion
either alone or in conjunction with one or more of
the agents in #8 and # 9 above.
11. Six months of continuous individual
psychotherapy, conducted at least twice monthly
for minimum 45 minute sessions, and consisting of
a) clinician-defined cognitive-behavioral psycho-
therapy directed toward reducing conditioned fear
symptoms of PTSD; b) cognitive processing psy-
chotherapy for PTSD [39]; c) prolonged exposure
therapy for PTSD (imaginal, in vivo, and/or virtual
reality) [47,50]; or d) Eye movement desensitization
and reprocessing therapy for PTSD including a
trauma exposure component [40], with chart docu-
mentation of inadequate benefit despite concerted
effort. Other forms of individual or group psycho-
therapy are permitted but not required for inclu-
sion. (Patients who are unable to complete
6 months of psychotherapy may be included if the
cause of treatment cessation was that the risks of
further treatment, including intense psychological
suffering, outweighed the potential benefits of con-
tinuing the treatment).
12. All evidence based psychotherapy for PTSD
(cognitive behavioral, cognitive processing,
prolonged exposure, and eye movement
desensitization) has been completed a minimum of
3 months prior to enrollment.
13. Minimum baseline CAPS17 of 85 at entry, with a)
scores of at least 4 (combined frequency and
severity) on at least one symptom from each
cluster (intrusion, avoidance and hyperarousal); b)
score of 5 or more on CAPS17 items 4 or 5
(intense psychological distress or physiological
reactivity on exposure to a reminder of the
traumatic event); and c) no questionable validity
(QV) rating greater than 1 on any CAPS item.
14. Clinically significant impairment in occupational
functioning due to PTSD, manifested by one or
more of the following: a) Total federal (service
connected ≥70%), or State (SSI) disability
compensation for at least the past 2 years for PTSD;
b) global assessment of functioning score ≤45; c) no
period of full time gainful employment ≥3 months
in the past 5 years.
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functioning due to PTSD, manifested by one or
more of the following: a) little or no social activity
outside the household other than as necessary for
medical appointments, practical matters such as
grocery shopping, or to interact with other
veterans; b) reliable description by a spouse or
significant other, living with the patient, of repeated
avoidance/refusal to participate in customary social
engagements with friends, family or for recreational
activities due to PTSD; c) two or more verbal or
physical interpersonal altercations within the past
year requiring another person’s intervention to
prevent further escalation, or involving law
enforcement
16. Cohabitation with a spouse or significant other adult
person who a) can confirm the symptoms and
impairment from PTSD and lack of significant
symptomatic remission in the past 5 years; and b) is
willing to participate with the study psychiatrist in
answering questions for the life functioning in PTSD
scale (LFIPS) at scheduled follow-up visits; and c) is
willing to report unexpected adverse neurological or
psychiatric events to study investigators and if advised
by study investigators, assist the patient in accessing
necessary services to address these.
17. Willingness to have unexpected neurological or
psychiatric symptom shared with the study
psychiatrists and other study clinicians.
18. Other medical conditions must be stable for at least
1 year, (conditions that require intermittent use of
steroids or chemotherapy are excluded).
Exclusion criteria
Exclusion criteria include the following:
1. Suicide attempt in the last 2 years and/or presence
of a suicide plan (an answer of ‘Yes’ to Question C4
in Section C-Suicidality of MINI International
Neuropsychiatric Interview) [156].
2. Psychosis or bipolar disorder; significant acute or
ongoing risk for violence.
3. Patients primarily diagnosed with DSM-IV-TR Axis
I disorder other than PTSD as determined by the
MINI.
4. Within the 3 months prior to enrollment, subject
has started a new psychotherapy program.
5. Alcohol or illicit substance use disorder within the
last 6 months, unstable remission of substance
abuse, or chart evidence that comorbid substance
use disorder could account for lack of treatment
response.
6. Current significant neurological conditions,
including epilepsy, stroke, movement disorder;history of serious head injury with loss of
consciousness.
7. Patients with uncontrolled medical conditions (such
as hypertension, diabetes, and infection).
8. Uncontrolled chronic pain.
9. Baseline Montgomery Asberg Depression Rating
Scale (MADRS) [157] of ≥28.
10. Patients who are receiving anticoagulation therapy.
11. Significant abnormality on preoperative structural
brain MRI.
12. Electroconvulsive therapy (ECT) in the past
6 months.
13. Contraindications to MRIs or the need for
recurrent body MRIs.
14. Immunosuppression.
15. Patients who are not appropriate candidates for
general anesthesia and/or DBS surgery.
16. Current pursuit of new or increased disability
compensation for PTSD.
17. Has cardiac pacemaker/defibrillator, implanted
medication pump, intracardiac lines, any
intracranial implants (aneurysm clip, shunt,
cochlear implant, electrodes) or other implanted
stimulator.
18. Patient has had past cranial neurosurgery.
19. Patient unable to discontinue therapeutic
diathermy.
20. Use of other investigational drugs or psychotropic
herbs within 30 days of baseline.
21. Patients suffering from a neurovascular condition or
other intracranial process.
22. Patients suffering from a condition associated with
a significant cognitive impairment.
An inclusion criterion perhaps somewhat unique to this
study is the required participation of a cohabiting signifi-
cant other for the duration of the study. The purpose of
this aspect of the trial is first for safety purposes. We know
that electrical stimulation of the amygdala has the poten-
tial to cause changes in emotional, perceptual, and behav-
ioral functioning that subjects may not be completely
aware of, be able to describe, or be able to remember.
Given that this is the first attempt to target the amygdala
with long-term stimulation in patients with PTSD, we felt
it important to include an observer who knows the subject
and is with them most of the time to increase sensitivity
for detecting significant, unexpected adverse psychological
or behavioral effects. To further explain this role to the
significant other, an information sheet will be provided
that details specific symptoms to look for, along with ur-
gency of reporting and contact information of the investi-
gators as well as emergency resources. Second, we believe
from our own clinical experience that in many combat
veterans, PTSD often affects interpersonal, family, and
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ently by veterans and their family members. Thus, we have
constructed a scale for monitoring changes in interper-
sonal, social, and family functioning that permits assess-
ment of patient functioning from the perspective of the
patient and caregiver independently: the Life Functioning
in PTSD Scale (LFIPS) [see Additional file 2]. No data
concerning the significant other will be collected. Further-
more, the loss of the significant other during the trial will
not lead to the exclusion of the subject.
Baseline assessments
The following baseline assessments will be completed
over an extended 6-week baseline period after patients
have given informed consent for inclusion, but before
deep brain stimulator implantation:
1. demographics,
2. medical history (includes family history),
3. medication history,
4. physical exam,
5. neurological exam,
6. lab screening including urine toxicology,
7. 12 lead EKG,
8. MRI scan (to exclude brain abnormalities),
9. Mini International Neuropsychiatric Interview
(MINI),
10. Combat Exposure Scale (CES),
11. Clinician Administered PTSD Scale (CAPS),
12. Hamilton Anxiety Rating Scale (HAM-A),
13. Montgomery-Asberg Depression Rating Scale
(MADRS),
14. Young Mania Rating Scale (YMRS),
15. Global Assessment of Functioning (GAF),
16. Clinical Global Impression of Severity &
Improvement (CGI-S, CGI-I),
17. Davidson Trauma Scale (DTS),
18. Columbia-Suicide Severity Rating Scale (C-SSRS),
19. Veterans Quality of Life Assessment (SF-36v),
20. Life Function in PTSD (LFIPS) (Additional file 2),
21. fluorodeoxyglucose (FDG) positron emission
tomographic (PET) brain imaging,
22. Amygdala DBS in Post-traumatic Stress disorder
Scale (ADIPS) neuropsychological tests (Additional
file 3)
23. neuropsychological battery (Additional file 4), and
24. electroencephalogram (EEG), 30 min awake and
sleep.
Randomization and blinding
There will be two study groups, A and B, corresponding
to either onset of active stimulation at 30 days or 90 days
post-implantation. Prior to enrollment of the first patient,
a computer algorithm will randomize each of the sixpotential subjects to either group A or B (three each), in
blocks of two. After the 1-month post-implantation EEG
telemetry session, the study neurophysiologist will learn
the group assignment of each subject. Subjects and all
other investigators will be blind to group assignment until
completion of the trial.
Outcome measures
The following measures will be used to assess symptom-
atic and functional outcomes [see Additional file 1 for
detailed description of measures 1 to 4]:
1. PTSD
a. Clinician Administered PTSD Scale (CAPS) [154]
b. Davidson Trauma Scale (DTS) [158]
2. Other psychiatric symptomology/morbidity
a. Montgomery-Asberg Depression Rating Scale
(MADRS) [157]
b. Young Mania Rating Scale (YMRS) [159]
c. Columbia-Suicide Severity Rating Scale (C-SSRS)
[160]
d. Hamilton Anxiety Rating Scale (HARS) [161]
3. Functioning/quality of life
a. Global Assessment of Functioning (GAF) [162]
b. Veterans Quality of Life Assessment (SF-36 V)
[163]
c. Life Function in PTSD (LFIPS) [see Additional
file 2]
4. Global outcome
a. Clinical Global Impression of Severity and
Improvement (CGI-S & CGI-I) [164]
5. Neuropsychological measures
a. Amygdala Deep Brain Stimulation in PTSD Scale
(ADIPS) [see Additional file 3]. Given that
amygdala DBS has not previously been performed
in humans with PTSD, we will also administer a
unique neuropsychological battery, the Amygdala
DBS in PTSD Scale (ADIPS), which was
developed for this study. This battery is designed
to systematically assess effects of electrode
insertion and stimulation on cognitive,
perceptual, emotional, and behavioral functions
known to be influenced by the amygdala and its
connections.
b. Neuropsychological Battery [see Additional file 4].
This battery consists of standardized measures of
attention, concentration, mental effort, verbal and
nonverbal memory, language, visuospatial
abilities, and executive skills. It will be
administered at baseline and at 6, 12, and
24 months postimplantation by a certified
neuropsychologist (RM).
6. Functional neuroimaging. Preoperatively, patients
will undergo a provocative PET-CT scan using
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baseline activity of the amygdalae, insulae, cingulate
and mPFC regions as in previous studies [109,110].
The PET procedure will include both a resting base-
line study, and a second ‘stimulus provocation study’,
during which patients will listen to an audio record-
ing of a ‘trauma script’ made prior to the scanning
session. The script will consist of the patient’s recita-
tion of a narrative of the trauma that caused PTSD
as in prolonged exposure therapy (for example,
[47]). Study Psychiatrists (RK, HS) will be present
during the PET session to ‘titrate’ symptom severity
to moderate, but not intolerable levels of arousal.
The same 18FDG PET scan paradigm will be re-
peated at 15 months postoperatively with optimal
DBS programming parameters. Since patients en-
rolled in this study have failed psychotherapy, in-
cluding exposure-based therapy, we expect that
changes in amygdala activation observed on the sec-
ond PET scan will not be the result of therapeutic
habituation from the first exposure session, but ra-
ther the effect of DBS. We will compare 18FDG PET
metabolism in the target regions between resting
and stimulus-exposed conditions, and differences
from preoperative to approximately one year after
chronic DBS. Our data analysis of the PET scans will
follow the described theory of parametric mapping
using SPM (Wellcome Trust Centre for Neuroimaging)
[165]. With this software, the PET data in each voxel
will be normalized and fitted in a linear statistical
model. Following the technique described by Shin and
others [102], our hypotheses will be evaluated as con-
trasts where the linear compounds of the model pa-
rameters will be evaluated with t-tests. This data is
then transformed into a z-score. Since we have strong
directional hypotheses (that DBS reduces amygdala
hyperactivity in PTSD patients), we will consider
z >3.09 (P <0.001 one tail, cluster level) as a statistically
significant difference. In this study, MM and DS will
conduct and analyze the PET scans.
7. Electroencephalographic changes. After the one-
month post-implantation EEG telemetry session,
patients will have routine EEGs performed monthly
for 15 months, and then every three months for the
last nine months of the study. These will be ana-
lyzed by our study neurologist, JC, with particular
attention paid to development of epileptiform
changes.
Study assessments will occur weekly for five months
after implantation, monthly for ten months, then every
three months for the final nine months. All study mea-
sures will be completed at baseline, and then repeated
as follows (see Additional files 1, 2, 3 and 4 for detaileddescriptions, and Additional file 5 for overall study
timeline):
1. Clinical monitoring and system status check at each
visit.
2. Stimulator adjustments, CAPS, MADRS, YMRS, C-
SSRS, LFIPS, ADIPS, CGI, vital signs, and EEG
monthly for 15 months, then every three months for
nine months.
3. GAF, SF-36 V, DTS, HAMA, ECG every three
months
4. Neuropsychological test battery at 6, 12, and
24 months
5. Resting and trauma script provoked PET Scan at
15 months
Surgery and the deep brain stimulation system
The DBS system to be used in this study is the Activa PC
pulse generator, a dual-channel programmable device.
The programmable stimulation settings are stored in the
device and are a specific combination of pulse width, rate,
and amplitude settings. The entire system, manufactured
by Medtronic, is comprised of implanted and nonim-
planted components. The components used in this proto-
col are as follows:
1. The implantable pulse generator (one/subject)
(Medtronic, Activa PC model 37601).
2. The intracranial leads (two/subject) (Medtronic,
model 3387). The leads contain the electrodes that
deliver the stimulation.
3. The lead extension wires (two/subject) (Medtronic,
model 37085). These make the connection between
the leads and the pulse generator.
4. Stimloc burrhole cover. This component is used to
secure the lead to the skull and cover the burrhole.
5. The N’Vision clinician programmer (Medtronic,
model 8840). This controls the pulse being
generated.
In this trial, we will use the device as it comes from the
manufacturer. The surgical implantation of the device fol-
lows the same technique used for movement disorder sur-
geries. The stimulation parameters that will be used in
this protocol are commonly used in movement disorder
and therefore the energy demand on the device will be the
same as typically used in movement disorders.
Following the standard surgical procedure for DBS
system implantation, the patients will undergo the
placement of a Leksell (Elekta, Atlanta, GA, USA)
stereotactic frame. The electrode trajectory will be
planned using stereotactic software (BrainLab, Munich,
Germany). We will follow a traditional transfrontal tra-
jectory (Figure 1). The transfrontal trajectory to the
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used for stereotactic amygdalotomy. We will implant
the DBS electrodes bilaterally in the BLn. A curvilinear
incision will be made bilaterally 3 cm lateral to midline
and 1 cm in front of the coronal suture. A burr hole will
be placed bilaterally with a high-speed drill for place-
ment of a Stimloc device (Medtronic, Minneapolis, MN,
USA) to hold the electrode in place. Once the Stimloc is
attached with the two self-tapping screws, the dura will
be opened. The dura will be coagulated back and the
cortex exposed, coagulated, and pierced. The electrode
3387 (Medtronic, Minneapolis, MN, USA) will then be
introduced down the cannula. All the contacts of the
electrode will then be stimulated at incremental voltages
up to 7 volts to confirm the absence of immediate side
effects by the study neurophysiologist (SK) while the pa-
tient is awake and is being examined by the study psych-
iatrist (RK, HS) and neurosurgeon (JPL). The left
electrode will be inserted and tested first for side-
effects, and then, the right electrode will be inserted and
tested. In the absence of serious adverse effects, the
stimulators will be turned off and the electrodes will then
be tunneled under the skin down to the upper chest area.
They will be connected to a dual-channel pulse generator
Activa PC (Medtronic, Minneapolis, USA).
After surgery, patients will be kept in the hospital for
approximately 3 days to ensure postoperative safety/sta-
bility. Then patients will return to the clinic for weekly
safety evaluations for the first five months. Stimulators
will be kept off in all patients for the first four weeks.
Then, once the EEG telemetry session described below
is complete, patients will be assigned randomly, in a
double-blind fashion (only the study neurophysiologist
will know) to have stimulation initiated at that 4-week
postoperative time point, or after an additional 2 months
(that is, 3 months postoperatively).
Electroencephalogram telemetry session and deep brain
stimulation initiation
At week 3 or 4, before initiation of experimental stimu-
lation, each subject will be admitted to the Neurology
EEG Telemetry Unit under the direction of JC for test-
ing of stimulus parameters with real-time EEG to rule
out after-discharges that would place patients at high
risk of seizures, changes in vital signs that would place
patients at risk of adverse health outcomes, changes in
cardiac rhythm on electrocardiogram (ECG), or changes
in behavior that would pose significant safety risk if they
were to occur at home in an unsupervised setting. Dur-
ing the telemetry session, the electrodes will be initially
stimulated at 2.5 V, 120-μsec pulse width, and 160-Hz
frequency. The amplitude will then be progressively
increased slowly to a maximum of 7 V. The pulse width
will then be increased to a maximum of 210 μsec.Finally, the frequency will be increased to a maximum
of 200 Hz. Side effects will be specifically noted
throughout the session. If a serious side effect is noted,
the last parameter changed will be kept at a maximum
of 60% of the threshold value during subsequent long-
term stimulation, and the other parameters will not be
increased. For instance, if an after-discharge is noted for
the first time at 5 V, the patient will continue in the
study following our protocol, but the stimulation pa-
rameters will be kept below 3 V.
After the telemetry session, the DBS treatment will be
initiated in a staggered fashion. Following the operation,
patients will be randomized into two groups of three sub-
jects. The first group will undergo therapeutic stimulation
beginning 30 days postoperatively. The second group will
start the stimulation at 90 days postoperatively. All the pa-
tients will undergo programming sessions of the same
duration whether actual stimulation is provided or not,
and the patients, the neurosurgeon, and the psychiatrists
performing the evaluations will be kept blind to the treat-
ment assignment.
We will also perform monthly EEGs for early detection
of newly developed epileptiform discharges after initi-
ation of stimulation. Subjects with newly developed epi-
leptiform discharges will be terminated from the study
and managed clinically.
Deep brain stimulation programming
Following the initiation of stimulation, stimulation pa-
rameters will be adjusted based upon the patient’s CAPS
scores and other aspects of response to DBS therapy.
Only one parameter can be changed at a study visit. The
neurophysiologist performing the programming will be
provided with the CAPS score and will adjust the pa-
rameters, based on the following protocol (sham adjust-
ments will be made during the first 2 months in subjects
who are randomized to initiation of stimulation at
90 days post-implantation):
1. amplitude increase,
2. amplitude increase,
3. pulse width increase, then
4. frequency change.
Any further programming changes will be based on the
patient’s CAPS scores, the response to DBS therapy, and
the clinical judgment of the study team. In order to prevent
any damage to the neural tissue, we will keep the charge-
density threshold below 30 microcoulombs/cm2/phase. The
programming device automatically provides measurement
warning if this threshold is exceeded. Following every
change, the patients will be monitored for any side effects.
The parameters will be reverted if the subject experiences
any sustained side effects.
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Patients enrolled in the study will be followed at least on
a biannual basis indefinitely by the study psychiatrist
and/or the study neurosurgeon after the completion of
the study. In addition, the patient will continue to follow
up with his treating psychiatrist. The frequency of the
visits will be adjusted on the basis of the clinical care
needs. All patients completing the protocol will be asked
in a future IRB submission to provide long-term follow-
up assessment data for publication to contribute to the
literature on DBS for psychiatric disorders.
Implant replacement
The study is budgeted for the replacement of one pulse
generator per subject. Following the study, the components
of the implant will be replaced indefinitely based on clinical
needs. The cost will be incurred by the clinical budget of
the VA since this will constitute clinical care of the patient.
If FDA approval is granted for the indication and the
patient wishes to continue the therapy, a depleted pulse
generator will be replaced in accordance with the FDA-
approved label. If FDA approval is not granted or if the ap-
plication falls outside the FDA-approved label, a decision
will be made based on the clinical needs of the patient. If
the treating psychiatrist determines that a replacement is in
the best interest of the patient, a new implant will be of-
fered. If, after informed consent, the patient agrees with the
procedure, the generator will be replaced as an off-label use
of a commercially available device. The device (Activa DBS,
Medtronic Inc) described in this protocol has been com-
mercially available since 1997. There are no modifications
brought to the implant for the application in PTSD; it is
used as manufactured and delivered. In our routine clinical
practice at GLA, several patients have undergone the place-
ment of this implant for off-label use. This occurs primarily
in the treatment of intractable pain syndrome or of move-
ment disorders that are not described in the current FDA-
approved labels. In these cases, the clinicians offer the
off-label therapy to patients that have never undergone
DBS. Under the current research protocol, the clinicians
will have the added benefit of knowing the patient’s
response to the therapy prior to offering an off-label re-
placement of the generator. The generator replacement is a
lower-risk procedure performed under local anesthesia.
Data analysis
This pilot study involves a small number of patients and
no formal treatment hypothesis will be tested. Demo-
graphics of the patients along with baseline data and
clinical information will be recorded and reported. As-
sessment of psychological scales and neuropsychiatric
tests will be conducted according to the recommended
methodology. We will compare the patients’ psycho-
logical scale scores with their baseline scores mainly forsafety reasons and to ensure that our subjects are not
worsening. To that end, the primary outcome measure
will be the CAPS at 12 months follow-up compared to
baseline. We will also analyze responders versus nonre-
sponders to determine if any predictors can be identi-
fied. For this purpose, a clinical response will be defined
as a 30% reduction in CAPS [154] from baseline and a
CGI-I [164] score of 1 (very much improved) or 2
(much improved).
Study aims
The primary aim is to assess the safety and identify ad-
verse events of BLn DBS for treatment-resistant PTSD.
Safety assessments include the following:
1. Frequency and severity of all adverse events
including physiological, neurological and
psychological/neuropsychological (see below).
2. Occurrence of adverse events in relation to DBS
amplitude, frequency and pulse width.
3. Occurrence of electrophysiological events in relation
to DBS amplitude, frequency and pulse width.
4. Electroencephalographic changes over time.
The secondary aim is to assess the effect of BLn DBS
in treatment-resistant PTSD on psychiatric symptoms
and quality of life using measures detailed below. A re-
duction of PTSD symptoms, as evidenced by the CAPS
score, with a 30% reduction from baseline is defined as
a response. For this study, the CAPS for DSM-IV will be
used, as the protocol was developed before publication
of the DSM-5 [166] or the CAPS for DSM-5. The effects
of BLn DBS on other psychiatric and neuropsychiatric
functions will be assessed during the course of stimula-
tion, and changes in either beneficial or adverse direc-
tions recorded and tabulated.
The third study aim will be to assess changes in brain
metabolism by comparing the 18FDG PET scan obtained
before implantation to that obtained 15 months post-
implantation. Regions of interest will be the bilateral
amygdalae, insulae, anterior cingulate gyri (and subre-
gions), and other portions of vmPFC.
Adverse events monitoring
A serious adverse event (SAE) is defined by any of the
following:
1. results in death,
2. is life threatening,
3. requires hospitalization or prolongs existing
hospitalization,
4. results in significant disability/incapacity,
malignancy, or
5. requires an intervention to prevent impairment.
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above. Both anticipated (that is, listed in the informed
consent form) and unanticipated AEs will be recorded.
The study includes an independent Data Safety Moni-
toring Board appointed by the IRB at our institution. Once
an AE is identified, the primary concern will be to attend
the subject and address the problem and ensure safety.
Immediately upon discovery of an SAE, the primary inves-
tigator will inform the DSMB, the IRB, and the FDA. The
IRB and the DSMB will also be promptly informed of the
occurrence of any AEs via review of case report forms
completed at each visit for all included subjects.
Anticipated adverse events, complications, and
side effects
Surgery
Patients will be informed that implantation of a DBS sys-
tem involves the following risks: postoperative pain, stress,
or discomfort; intracranial hemorrhage; subcutaneous
hemorrhage or seroma; infection; seizure or convulsions;
aphasia; cranial neuropathy; amnesia; paralysis; stroke;
death; cerebrospinal fluid leakage; additional neurosurgical
procedure to manage one of the above complications or
to replace a fractured lead; excoriation of the implant; and
additional surgical procedure to replace the pulse
generator.
Amygdala stimulation
More specific to this study, anticipated adverse events
may be subdivided into five areas:
1. Emotional - happiness, even mania, sense of calm,
anxiety, fear, anger, depression, sense of doom, or
suicidal thoughts. Lack of anxiety or even lack of
normal fear reactions to potentially dangerous situa-
tions are possible side effects.
2. Sensory and perceptual - seeing, hearing, feeling,
smelling, or tasting things that are not there; feeling
as if you are separate from your body; déjà vu (feel-
ing as if a place that should be unfamiliar is familiar);
jamais vu (the opposite of déjà vu); other changes in
the way things look, sound, feel, taste, or smell; or
out-of-body experiences.
3. Behavioral - increased or decreased appetite, sleep,
or sexual interest; suddenly starting to run; increased
or decreased interest or participation in religion, pol-
itics, moral issues, or writing; tendency to put non-
food objects in the mouth; aggressive behavior
toward self or others; or suicide attempt.
4. Neuropsychological - improvement or worsening of
attention, memory, language function, visual-spatial
abilities, logical reasoning, risk-taking, or ability to
understand emotions or other psychological issues
in others.5. Neurological (seizures) - risk of seizures from elec-
trical stimulation of the amygdala. These seizures
may arise as a result of the direct stimulation of the
brain tissue or as a result of modifications (such as
scarring or sclerosis) of the brain tissue over time.
Risk reduction measures
Surgery
The surgical procedure involved in deep brain stimulation
electrode placement is considered to carry a low risk. In
order to further reduce the risks of complication associ-
ated with the surgery we are performing the following
procedures:
1. Transfrontal trajectory. The transfrontal trajectory
employed has been used in more than a thousand
cases of stereotactic amygdalotomies [138]. Using
this trajectory (Figure 1), the incidence of
complications from the surgery is comparable to
that of DBS for movement disorders.
2. Strict exclusion criteria of ‘higher risk’ patients.
Those patients would carry a higher risk of
complication related to the use of anticoagulation or
the presence of a medically uncontrolled condition
(for example, diabetes, hypertension, or infection).
By eliminating those patients, we will significantly
reduce the risks of major complications.
3. Use of computer-assisted stereotactic targeting. This
technique allows us to precisely predict and deter-
mine the trajectory followed by the electrode on the
preoperative MRI. Using this technique, we can
avoid major vessels and the ventricles. This will fur-
ther reduce the risks of hemorrhage and
mistargeting.
4. Intensive postoperative care. This includes the use of
an immediate postoperative CT scan to rule out an
intracranial complication and the admission of every
patient to the intensive care unit for frequent
neurological examination. These steps will permit us
to promptly recognize the presence of a
complication.
5. Use of perioperative antibiotics. Antibiotics will be
administered one hour prior to incision and then for
a period of 24 hours.
Neuromodulation
The side effects associated with neuromodulation are typ-
ically reversible with adjustments given the nonlesional
nature of high-frequency stimulation. In order to reduce
the risks associated with neuromodulation, we will per-
form the following procedures:
1. The protocol includes a monitoring session at the
beginning of the stimulation where the patient
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oximetry while the stimulation parameters are
slowly increased (see above). This session will be
critical to monitor for the occurrence of any
afterdischarges or electrographic seizures. The risk
of electroconvulsion is significantly reduced in the
absence of afterdischarges. Bawden and Racine [167]
reported that electrical stimulation of the amygdala
with a charge density below the threshold to
produce afterdischarges does not significantly lower
the afterdischarge threshold in rats over time. Other
authors have reported that electrical stimulation of
the amygdala and the hippocampus raise the
threshold for electroconvulsion therefore leading to
protection against seizure. In humans, chronic high-
frequency stimulation of the mesiotemporal struc-
tures has been shown to raise the seizure threshold.
Velasco et al. [133] have reported that the chronic
high-frequency stimulation of the normal or sclerotic
hippocampus reduces the incidence of seizures in
refractory epileptic patients without causing side
effects. Patients with a normal hippocampus had a
95% seizure reduction; patients with a sclerotic
hippocampus had a 50 to 70% seizure reduction.
2. The protocol includes a systematic plan for
monitoring, with specified operational criteria for
interventions to manage the two most serious
categories of risk related to amygdala
neuromodulation: seizures/epilepsy, and serious
psychiatric disturbance, including suicidal or
aggressive behavior. Monthly EEG surveillance will
be performed to evaluate for the occurrence of
epileptiform discharges.
3. DBS will be initiated at low (subtherapeutic)
parameters and will be raised slowly over a period of
several days.
4. During a programming session, only one parameter
(amplitude, pulse width or frequency) will be
increased.
5. Following an adjustment in the parameters, the
patient will be kept in the clinic for at least 30 min
to make sure that no acute changes related to
neuromodulation occur.
6. The inclusion of patients’ significant others will
allow early detection and management of adverse
psychiatric or neurological effects that develop
between clinic visits.
7. If side effects are occurring with new stimulation
settings, the parameters will be decreased until the
side-effects have resolved. This follows our current
clinical programming protocol for our patients
treated with DBS.
8. Subjects will be provided with an emergency
identification card. The same card will also beprovided to significant others participating in the
study and, in addition, significant others will be
provided with an information sheet that describes
potential adverse psychiatric and neurological effects
of DBS, and provides guidelines on how to respond.
9. Beginning not earlier than six months after
implantation, patients who have experienced benefit
from stimulation without treatment interfering
adverse effects, and who are able to understand the
nature of the devices and treatment well enough,
will be offered an external controller they can use to
verify the device on their own. This will permit
patients to have an additional safeguard against
unexpected adverse effects that emerge between
visits, particularly if patients want to travel
significant distances away from the medical center.
Management of potential complications
and therapy cessation
Seizures
Because the stimulation parameters chosen in this study
will avoid the induction of afterdischarges, it is unlikely
that kindled seizures will occur. However, given the pos-
sible kindling effect of chronic DBS of the amygdalae,
monthly EEG studies will be performed to detect epilep-
tiform discharges before epilepsy would be fully estab-
lished. Subjects with confirmed epileptiform discharges,
such as sharp waves, spike and slow waves, polyspikes,
or a full seizure will not be kept in the study. The EEG
will be interpreted by a board-certified clinical epileptol-
ogist (JC).
Any patients who suffer from a seizure will follow up
with our epileptologist on a monthly basis for a period
of six months, and then every three months for the dur-
ation of the trial. Following the completion of the trial,
the patient will continue to be followed up as clinically
indicated.
Worsening psychiatric condition
The therapy aims at improving the psychiatric condition
of the patient; however, our pre-specified algorithm will
assist in caring for patients who may experience worsen-
ing of their condition while on therapy. The decision to
discontinue a patient‘s participation in the study due to
worsening symptoms will be individualized, since it is pos-
sible that some symptom or function domains will im-
prove at the same time that others will worsen, and that
some subjects will prefer to remain in the trial despite
temporary worsening of their condition. For instance, pa-
tients with overall improvements may face temporary
challenges related to higher expectations from their social
environment (for example, employment or home respon-
sibilities) and this could lead to deterioration on different
scales. Significant worsening in psychological status will
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scales (and/or clinically significant change). The manage-
ment will follow a predetermined algorithm.
The presence of significant suicidal/homicidal im-
pulses will be evaluated at baseline via clinical interview,
including standard VA Computerized Patient Record
System templates for suicide and violence risk assess-
ment, and the CSSRS-Baseline [160]. Subjects with
more than low levels of risk for suicide or violence/
homicide will be excluded from participation. During
the study, study psychiatrists will conduct clinical as-
sessment of suicidal and violent/homicidal thoughts at
each visit, and questions about these risks will also be
asked of significant others. Significant others will be
asked to contact study investigators immediately and, if
necessary, call 911 or contact the VA Suicide Hotline
should these issues emerge between visits. At monthly
visits for the first year, and every 3 months during the
second year, the CSSRS-Since Last Visit is already in-
cluded in the study protocol. Planned interventions for
emergent suicidal or homicidal/violent events will be
individualized based on specific findings and circum-
stances, but will conform to the following general
algorithm:
1. New suicidal or violent thoughts without intent or
plan to act:
a. identify and manage intercurrent nonstudy
related medical, psychological, or social factors;
b. assess for presence of clinical syndromes such as
major depression, mania, or psychosis, and
intervene with psychotherapy or medications as
clinically indicated; and
c. adjust DBS parameters to prior settings that were
not associated with such thoughts/impulses, or
turn stimulator(s) off if this occurs at the first
initiation of active stimulation.
2. New suicidal or violent/homicidal thoughts with
plan or intent to act, or commission of suicide
attempt or violent act: immediate psychiatric
hospitalization, voluntary or involuntary as per
standard legal guidelines applicable to all veterans.
Then, in the hospital, 1a, 1b, and 1c, are followed as
above.
3. Actual completed suicide or homicide: support will
be provided to the caregiver or patient and
caregiver, respectively; the VA’s Suicidal Behavior
and Violence Committee will be notified; the IRB,
DSMB, and FDA will be notified; all other patients
and significant others involved in the trial will be
notified; no further enrollment will be permitted
until a full assessment of the relationship of the
incident to the study has been completed; and
overall continuation of the trial will depend on theoutcome of thorough investigation and IRB/DSMB
recommendations.
Therapy cessation
The decision to stop the stimulation unilaterally (one
electrode) or bilaterally (both electrodes) will be made
on a case-by-case basis and the IRB will be informed.
The decision to stop the stimulation is not necessarily ir-
reversible and could be used in certain cases to confirm
that a specific symptom is not caused by the stimulation.
Patients who stop the stimulation, but agree to follow-
up, will be seen at the same frequency, following the
protocol. As a general guideline, cases where the stimu-
lation would be stopped include:
1. After being fully informed, the patient wishes to stop
the stimulation.
2. The patient is suffering from a deterioration of his
psychological condition thought to be related to the
stimulation. He has been unresponsive to changes in
DBS parameters.
3. The stimulation is causing intolerable side effects
unresponsive to changes in DBS parameters.
4. The patient has suffered from a seizure as a result of
DBS.
5. The patient has to undergo treatment for a life-
threatening condition and stimulation may interfere
with the treatment.
6. The patient has become seriously non-compliant
with the course of therapy (for example, missing sev-
eral appointments, engaging in behavior that places
him or others at risk related to the device, or serious
substance-use disorder).
Discussion
Treatment-resistant PTSD, particularly among combat
veterans, is a serious condition associated with substantial
morbidity and likely early mortality. While there are ef-
fective treatments, particularly trauma-focused cognitive-
behavioral psychotherapies, that can help many of these
patients, there are individuals who do not benefit from, or
tolerate, these and psychopharmacologic interventions.
The rationale for amygdala DBS is well supported both
from preclinical direct studies of amygdala function, and
the success of BLn DBS in a rat model of PTSD by our
own group. Human functional neuroimaging findings are
also strongly suggestive of amygdala hyperactivity as an
underlying substrate of persistent PTSD, particularly the
symptoms of stimulus-associated emotional and auto-
nomic hyperarousal. While alternative targets for neuro-
modulation with DBS in PTSD have been proposed [146],
our model, proposing high-frequency DBS of the bilateral
BLn in treatment-refractory combat veterans, has the best
overall support. It is feasible both from a technical
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clinical report of DBS with the same target for another
treatment-refractory behavioral condition [142].
The main concern is that the potential benefit of BLn
DBS comes with the risks of any DBS neurosurgical pro-
cedure, as well as risks associated with long-term neuro-
modulation. Among the surgical risks, we foresee the
risk of seizures to be theoretically greater than seen in
other DBS applications in neurology and psychiatry.
However, the case noted above [142], in which stimula-
tion parameters similar to those planned for our study
were not associated with seizures, and the findings of
our literature review above indicating that much higher
charge densities than planned for our devices are needed
to trigger or kindle amygdala seizures in non-epileptic
individuals, mitigate this risk. Further, our protocol in-
cludes a baseline stimulus-testing EEG telemetry session
and monthly EEGs during chronic stimulation, all moni-
tored by an epileptologist involved in our study. In terms
of the risks of neuromodulation, our protocol involves
extensive systematic monitoring using both validated
and novel psychiatric and neuropsychiatric measures de-
signed to identify changes in emotion, perception, think-
ing, behavior, and autonomic and vegetative function
that could be influenced by amygdala circuitry neuromo-
dulation. Given that this is the first trial of BLn DBS in a
psychiatrically ill population, this appears justified. As
noted, our study includes the fairly unique requirement
that patients who enroll in the study do so in conjunc-
tion with a co-habiting significant other willing to work
with the investigative team in monitoring for both fore-
seeable and unforeseeable safety risks. Our protocol’s
emphasis on improving both function and symptoms
also involves asking the significant others to provide in-
put about changes in veterans’ social functioning that
will help us better understand how amygdala neuromo-
dulation changes PTSD and affects human behavior.
The study includes two specific elements that hope to
add to the understanding of brain-behavior relationships
from our intervention. First, the double-blind staggered-
onset sham-stimulation phase will allow us to observe
changes associated with electrode implantation without
electrical neuromodulation; what others have referred to
as a ‘microlesioning effect’. This will also allow us to
separate out nonspecific aspects of study involvement
from specific effects of DBS. The study also includes
prestimulation and poststimulation PET scanning ses-
sions, each of which includes scans done before and
after exposure to a trauma narrative as has been done in
other functional neuroimaging studies of PTSD. We
chose to use the 18FDG PET paradigm because it per-
mits assessments of change in stimulus-driven function-
ing of the brain for longer time epochs than either 15O2
PET or fMRI. We feel that this more closely models theclinical difficulty patients with PTSD face; it is not just the
nature and intensity of reactions, but their duration and
ensuing effect on functioning that is important. We
considered including a pre-implantation, as well as a pre-
stimulation, post-implantation PET study. While this would
be ideal from a scientific perspective, we decided that the
additional patient burden was not justified given the com-
pletely uncharted territory of this pilot investigation.
The principal limitation of this study protocol is the ex-
tensive burden of monitoring required of patients. Weekly
visits for the first five months, and monthly thereafter for
another 19 months, are required of consenting subjects.
Procedures at the monthly visit include fairly extensive bat-
teries of psychiatric and neuropsychiatric tests that - while
they may be less cumbersome with repetition - could still
be fairly trying. The additional requirement for frequent
EEGs, two PET scans, and three neuropsychological testing
batteries add additional burden. For the patients who would
qualify - combat vets disabled by their illness with object-
ively confirmed severe symptomatology and social function
impairment that has not resolved despite extensive stand-
ard treatment efforts - asking them to do this is difficult
and will require intensive involvement on the part of study
team. To compensate patients for the burdens of the study
investigations, we have been accorded funding to pay
them transportation costs, and, when necessary, overnight
accommodations, including for significant others. The
principal investigators have made a commitment to be
available - or to provide adequate clinical coverage when
away - to subjects and their significant others 24/7 for the
duration of the study. An independent data safety moni-
toring board will provide oversight throughout the study
as well.
We hope that our study will benefit the patients who
participate. We also hope that BLn DBS is found to be
safe in this population and that it can be extended in fu-
ture studies to other populations of individuals suffering
from treatment-refractory PTSD.
Trial status
The study is currently recruiting subjects.
Regulatory issues
The device (Activa DBS, Medtronic Inc) described in
this protocol has been commercially available since
1997. In this study, the device will be used for patients
suffering from PTSD, which is not an approved indica-
tion at this time; approval for use in this study is granted
under IDE #G120095/S001 (Revised 5-8-14 under
G120095/R002). The device does have pre-market
approval for use in Parkinson’s disease and essential
tremor for which over 70,000 patients have undergone
implantation and subsequent treatment worldwide. DBS
received Humanitarian Device Exemption for use in
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order (HDE #050003).
In this trial, the device and the individual components
will not be modified - it will be kept in its packaging until
implantation and will be used as it comes from the manu-
facturer. The surgical implantation of the device follows
the same technique as used for movement disorder
surgery
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